메뉴 건너뛰기




Volumn 9, Issue 16, 2008, Pages 2881-2891

Orally disintegrating selegiline for the treatment of Parkinson's disease

Author keywords

Monoamine oxidase B; Orally disintegrating selegiline; Parkinson's disease; Selegiline; Zydisr selegiline

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; LAZABEMIDE; LEVODOPA; METHAMPHETAMINE; MOFEGILINE; NORSELEGILINE; OLANZAPINE; OTRASEL; PLACEBO; RASAGILINE; SELEGILINE; UNCLASSIFIED DRUG; XILOPAR;

EID: 56749155674     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.16.2881     Document Type: Review
Times cited : (6)

References (65)
  • 1
    • 0029435462 scopus 로고
    • Prevalence of Parkinson's disease in the elderly: The Rotterdam Study
    • de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;45(12):2143-6
    • (1995) Neurology , vol.45 , Issue.12 , pp. 2143-2146
    • de Rijk, M.C.1    Breteler, M.M.2    Graveland, G.A.3
  • 2
    • 0032946784 scopus 로고    scopus 로고
    • Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990
    • Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52(6):1214-20
    • (1999) Neurology , vol.52 , Issue.6 , pp. 1214-1220
    • Bower, J.H.1    Maraganore, D.M.2    McDonnell, S.K.3    Rocca, W.A.4
  • 3
    • 33846572874 scopus 로고    scopus 로고
    • Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
    • Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6
    • (2007) Neurology , vol.68 , pp. 384-386
    • Dorsey, E.R.1    Constantinescu, R.2    Thompson, J.P.3
  • 4
    • 32544432029 scopus 로고    scopus 로고
    • Non-motor symptoms of Parkinson's disease: Diagnosis and management
    • Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5(3):235-45
    • (2006) Lancet Neurol , vol.5 , Issue.3 , pp. 235-245
    • Chaudhuri, K.R.1    Healy, D.G.2    Schapira, A.H.3
  • 5
    • 18844394828 scopus 로고    scopus 로고
    • Pathogenesis of nigral cell death in Parkinson's disease
    • Przedborski S. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord 2005;11(Suppl 1):S3-7
    • (2005) Parkinsonism Relat Disord , vol.11 , Issue.SUPPL. 1
    • Przedborski, S.1
  • 6
    • 0032497504 scopus 로고    scopus 로고
    • Parkinson's disease. First of two parts
    • Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339(15):1044-53
    • (1998) N Engl J Med , vol.339 , Issue.15 , pp. 1044-1053
    • Lang, A.E.1    Lozano, A.M.2
  • 7
    • 73049129373 scopus 로고
    • L-3,4-dioxyphenylalanin (=DOPA) Effekt bei der Parkinson-Akinese.
    • Birkmayer W, Hornykiewicz O. L-3,4-dioxyphenylalanin (=DOPA) Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 1961;73:787-8
    • (1961) Wien Klin Wochenschr , vol.73 , pp. 787-788
    • Birkmayer, W.1    Hornykiewicz, O.2
  • 8
    • 38349084850 scopus 로고    scopus 로고
    • Half a century of antidepressant drugs: On the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I. Monoamine oxidase inhibitors
    • Lopez-Munoz F, Alamo C, Juckel G, Assion HJ. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I. Monoamine oxidase inhibitors. J Clin Psychopharmacol 2007;27(6):555-9
    • (2007) J Clin Psychopharmacol , vol.27 , Issue.6 , pp. 555-559
    • Lopez-Munoz, F.1    Alamo, C.2    Juckel, G.3    Assion, H.J.4
  • 9
    • 56749090546 scopus 로고
    • Liver damage concurrent with iproniazid administration
    • Zetzel L, Kaplan H. Liver damage concurrent with iproniazid administration. N Engl J Med 1958;258(24):1209-11
    • (1958) N Engl J Med , vol.258 , Issue.24 , pp. 1209-1211
    • Zetzel, L.1    Kaplan, H.2
  • 10
    • 56749145816 scopus 로고
    • Hepatic and renal damage with azotemia associated with iproniazid administration
    • Spellberg MA, Frankel JJ. Hepatic and renal damage with azotemia associated with iproniazid administration. Am J Gastroenterol 1962;37:64-9
    • (1962) Am J Gastroenterol , vol.37 , pp. 64-69
    • Spellberg, M.A.1    Frankel, J.J.2
  • 11
    • 0001137465 scopus 로고
    • Hypertensive crisis due to monoamine-oxidase inhibitors
    • Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 1963;2(7313):849-50
    • (1963) Lancet , vol.2 , Issue.7313 , pp. 849-850
    • Blackwell, B.1
  • 13
    • 30444437749 scopus 로고    scopus 로고
    • Monoamine oxidase: Isoforms and inhibitors in Parkinson's disease and depressive illness
    • Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 2006;147(Suppl 1):S287-96
    • (2006) Br J Pharmacol , vol.147 , Issue.SUPPL. 1
    • Youdim, M.B.1    Bakhle, Y.S.2
  • 14
    • 76549174465 scopus 로고
    • Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer
    • Knoll J, Ecseri Z, Kelemen K, et al. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 1965;155(1):154-64
    • (1965) Arch Int Pharmacodyn Ther , vol.155 , Issue.1 , pp. 154-164
    • Knoll, J.1    Ecseri, Z.2    Kelemen, K.3
  • 15
    • 0015274536 scopus 로고
    • Some puzzling pharmacological effects of monoamine oxidase inhibitors
    • Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972;5:393-408
    • (1972) Adv Biochem Psychopharmacol , vol.5 , pp. 393-408
    • Knoll, J.1    Magyar, K.2
  • 16
    • 0016414699 scopus 로고
    • The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil
    • Birkmayer W, Riederer P, Youdim MB, Linauer W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm 1975;36(3-4):303-26
    • (1975) J Neural Transm , vol.36 , Issue.3-4 , pp. 303-326
    • Birkmayer, W.1    Riederer, P.2    Youdim, M.B.3    Linauer, W.4
  • 17
    • 0022365018 scopus 로고
    • Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A longterm study
    • Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 1985;64(2):113-27
    • (1985) J Neural Transm , vol.64 , Issue.2 , pp. 113-127
    • Birkmayer, W.1    Knoll, J.2    Riederer, P.3
  • 18
    • 0028858370 scopus 로고
    • The effect of deprenyl and levodopa on the progression of Parkinson's disease
    • Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38(5):771-7
    • (1995) Ann Neurol , vol.38 , Issue.5 , pp. 771-777
    • Olanow, C.W.1    Hauser, R.A.2    Gauger, L.3
  • 19
    • 0027530638 scopus 로고
    • Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
    • The Parkinson Study Group
    • The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328(3):176-83
    • (1993) N Engl J Med , vol.328 , Issue.3 , pp. 176-183
  • 20
    • 0024343466 scopus 로고
    • The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
    • Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245(4917):519-22
    • (1989) Science , vol.245 , Issue.4917 , pp. 519-522
    • Tetrud, J.W.1    Langston, J.W.2
  • 21
    • 0345019854 scopus 로고    scopus 로고
    • Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group
    • Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998;51(2):520-5
    • (1998) Neurology , vol.51 , Issue.2 , pp. 520-525
    • Palhagen, S.1    Heinonen, E.H.2    Hagglund, J.3
  • 22
    • 0030832391 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and pharmacodynamics of selegiline. An update
    • Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 1997;33(2):91-102
    • (1997) Clin Pharmacokinet , vol.33 , Issue.2 , pp. 91-102
    • Mahmood, I.1
  • 23
    • 0036230653 scopus 로고    scopus 로고
    • The influence of metabolism on the MAO-B inhibitory potency of selegiline
    • Haberle D, Szoko E, Magyar K. The influence of metabolism on the MAO-B inhibitory potency of selegiline. Curr Med Chem 2002;9(1):47-51
    • (2002) Curr Med Chem , vol.9 , Issue.1 , pp. 47-51
    • Haberle, D.1    Szoko, E.2    Magyar, K.3
  • 24
  • 25
    • 0030300163 scopus 로고    scopus 로고
    • Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research
    • Yasar S, Goldberg JP, Goldberg SR. Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research. J Neural Transm Suppl 1996;48:61-73
    • (1996) J Neural Transm Suppl , vol.48 , pp. 61-73
    • Yasar, S.1    Goldberg, J.P.2    Goldberg, S.R.3
  • 26
    • 0036894795 scopus 로고    scopus 로고
    • A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study
    • Parkinson Study Group
    • Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59(12):1937-43
    • (2002) Arch Neurol , vol.59 , Issue.12 , pp. 1937-1943
  • 27
    • 2342655732 scopus 로고    scopus 로고
    • A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease
    • Parkinson Study Group
    • Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61(4):561-6
    • (2004) Arch Neurol , vol.61 , Issue.4 , pp. 561-566
  • 28
    • 15844386001 scopus 로고    scopus 로고
    • Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial
    • Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947-54
    • (2005) Lancet , vol.365 , Issue.9463 , pp. 947-954
    • Rascol, O.1    Brooks, D.J.2    Melamed, E.3
  • 29
    • 13444302612 scopus 로고    scopus 로고
    • A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study
    • Parkinson Study Group
    • Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241-8
    • (2005) Arch Neurol , vol.62 , Issue.2 , pp. 241-248
  • 30
    • 48649093789 scopus 로고    scopus 로고
    • Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    • Clarke CE. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov Disord 2008;23(6):784-9
    • (2008) Mov Disord , vol.23 , Issue.6 , pp. 784-789
    • Clarke, C.E.1
  • 31
    • 36749021653 scopus 로고    scopus 로고
    • Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease
    • Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 2007;29(9):1825-49
    • (2007) Clin Ther , vol.29 , Issue.9 , pp. 1825-1849
    • Chen, J.J.1    Swope, D.M.2    Dashtipour, K.3
  • 32
    • 0027343342 scopus 로고
    • An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidaae type B (MAO-B) inhibitor, in Parkinson's disease
    • Myllyla VV, Sotaniemi KA, Aasly J, Sjaastad O, Rinne U, McIntyre T, et al. An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidaae type B (MAO-B) inhibitor, in Parkinson's disease. Adv Neurol 1993;60:676-80
    • (1993) Adv Neurol , vol.60 , pp. 676-680
    • Myllyla, V.V.1    Sotaniemi, K.A.2    Aasly, J.3    Sjaastad, O.4    Rinne, U.5    McIntyre, T.6
  • 33
    • 0029927070 scopus 로고    scopus 로고
    • Effect of lazabemide on the progression of disability in early Parkinson's disease
    • The Parkinson Study Group
    • The Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol 1996;40(1):99-107
    • (1996) Ann Neurol , vol.40 , Issue.1 , pp. 99-107
  • 34
    • 0002139122 scopus 로고
    • Zydis: A novel, fast dissolving dosage form
    • Virely P, Yarwood R. Zydis: a novel, fast dissolving dosage form. Manuf Chem 1990;(61):36-7
    • (1990) Manuf Chem , vol.61 , pp. 36-37
    • Virely, P.1    Yarwood, R.2
  • 35
    • 0345189359 scopus 로고    scopus 로고
    • A new formulation of selegiline: Improved bioavailability and selectivity for MAO-B inhibition
    • Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003;110(11):1241-55
    • (2003) J Neural Transm , vol.110 , Issue.11 , pp. 1241-1255
    • Clarke, A.1    Brewer, F.2    Johnson, E.S.3
  • 36
    • 0028577499 scopus 로고
    • Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites
    • Heinonen EH, Anttila MI, Lammintausta RA. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 1994;56(6 Pt 2):742-9
    • (1994) Clin Pharmacol Ther , vol.56 , Issue.6 PART 2 , pp. 742-749
    • Heinonen, E.H.1    Anttila, M.I.2    Lammintausta, R.A.3
  • 37
    • 0027264145 scopus 로고
    • Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition
    • Youdim MB, Riederer P. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm Gen Sect 1993;91(2-3):181-95
    • (1993) J Neural Transm Gen Sect , vol.91 , Issue.2-3 , pp. 181-195
    • Youdim, M.B.1    Riederer, P.2
  • 38
    • 0027981209 scopus 로고
    • Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal
    • Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. Synapse 1994;18(2):86-93
    • (1994) Synapse , vol.18 , Issue.2 , pp. 86-93
    • Fowler, J.S.1    Volkow, N.D.2    Logan, J.3
  • 39
    • 0031010732 scopus 로고    scopus 로고
    • Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites
    • Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 1997;25(6):657-62
    • (1997) Drug Metab Dispos , vol.25 , Issue.6 , pp. 657-662
    • Shin, H.S.1
  • 40
    • 0034772878 scopus 로고    scopus 로고
    • CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes
    • Hidestrand M, Oscarson M, Salonen JS, et al. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos 2001;29(11):1480-4
    • (2001) Drug Metab Dispos , vol.29 , Issue.11 , pp. 1480-1484
    • Hidestrand, M.1    Oscarson, M.2    Salonen, J.S.3
  • 41
    • 33645131794 scopus 로고    scopus 로고
    • Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl]
    • Yasar S, Justinova Z, Lee SH, et al. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl]. J Pharmacol Exp Ther 2006;317(1):387-94
    • (2006) J Pharmacol Exp Ther , vol.317 , Issue.1 , pp. 387-394
    • Yasar, S.1    Justinova, Z.2    Lee, S.H.3
  • 42
    • 0031886449 scopus 로고    scopus 로고
    • Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion
    • Mytilineou C, Leonardi EK, Radcliffe P, et al. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J Pharmacol Exp Ther 1998;284(2):700-6
    • (1998) J Pharmacol Exp Ther , vol.284 , Issue.2 , pp. 700-706
    • Mytilineou, C.1    Leonardi, E.K.2    Radcliffe, P.3
  • 43
    • 0031037786 scopus 로고    scopus 로고
    • L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro
    • Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem 1997;68(1):434-6
    • (1997) J Neurochem , vol.68 , Issue.1 , pp. 434-436
    • Mytilineou, C.1    Radcliffe, P.M.2    Olanow, C.W.3
  • 44
    • 0034731367 scopus 로고    scopus 로고
    • Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes
    • Mizuta I, Ohta M, Ohta K, et al. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 2000;279(3):751-5
    • (2000) Biochem Biophys Res Commun , vol.279 , Issue.3 , pp. 751-755
    • Mizuta, I.1    Ohta, M.2    Ohta, K.3
  • 45
    • 0024457355 scopus 로고
    • DATATOP: A multicenter controlled clinical trial in early Parkinson's disease
    • Parkinson Study Group
    • Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052-60
    • (1989) Arch Neurol , vol.46 , pp. 1052-1060
  • 46
    • 0025358344 scopus 로고
    • Selegiline in Parkinson's disease
    • Teravainen H. Selegiline in Parkinson's disease. Acta Neurol Scand 1990;81(4):333-6
    • (1990) Acta Neurol Scand , vol.81 , Issue.4 , pp. 333-336
    • Teravainen, H.1
  • 47
    • 0026596575 scopus 로고
    • Selegiline as initial treatment in de novo parkinsonian patients
    • Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992;42(2):339-43
    • (1992) Neurology , vol.42 , Issue.2 , pp. 339-343
    • Myllyla, V.V.1    Sotaniemi, K.A.2    Vuorinen, J.A.3    Heinonen, E.H.4
  • 48
    • 0027524961 scopus 로고
    • Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial
    • Allain H, Pollak P, Neukirch HC. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial. Mov Disord 1993;8(Suppl 1):S36-40
    • (1993) Mov Disord , vol.8 , Issue.SUPPL. 1
    • Allain, H.1    Pollak, P.2    Neukirch, H.C.3
  • 49
    • 0028824983 scopus 로고
    • Delayed development of symptomatic improvement by (-)-deprenyl in Parkinson's disease
    • Mally J, Kovacs AB, Stone TW. Delayed development of symptomatic improvement by (-)-deprenyl in Parkinson's disease. J Neurol Sci 1995;134(1-2):143-5
    • (1995) J Neurol Sci , vol.134 , Issue.1-2 , pp. 143-145
    • Mally, J.1    Kovacs, A.B.2    Stone, T.W.3
  • 50
    • 0036920181 scopus 로고    scopus 로고
    • MAO-B inhibitors for the treatment of Parkinson's disease
    • Movement Disorder Society
    • Movement Disorder Society. MAO-B inhibitors for the treatment of Parkinson's disease. Mov Disord 2002;17(Suppl 4):S38-44
    • (2002) Mov Disord , vol.17 , Issue.SUPPL. 4
  • 51
    • 0023475584 scopus 로고
    • The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor
    • Przuntek H, Kuhn W. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. J Neural Transm Suppl 1987;25:97-104
    • (1987) J Neural Transm Suppl , vol.25 , pp. 97-104
    • Przuntek, H.1    Kuhn, W.2
  • 52
    • 84996059578 scopus 로고
    • Selegiline and levodopa in early or moderately advanced Parkinson's disease: A double-blind controlled short- and long-term study
    • Sivertsen B, Dupont E, Mikkelsen B, et al. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study. Acta Neurol Scand Suppl 1989;126:147-52
    • (1989) Acta Neurol Scand Suppl , vol.126 , pp. 147-152
    • Sivertsen, B.1    Dupont, E.2    Mikkelsen, B.3
  • 53
    • 9044227267 scopus 로고
    • Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom
    • Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 1995;311(7020):1602-7
    • (1995) BMJ , vol.311 , Issue.7020 , pp. 1602-1607
    • Lees, A.J.1
  • 54
    • 0030899733 scopus 로고    scopus 로고
    • The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: An interim analysis of a Norwegian-Danish 5-year study. Norwegian-Danish Study Group
    • Larsen JP, Boas J. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian-Danish 5-year study. Norwegian-Danish Study Group. Mov Disord 1997;12(2):175-82
    • (1997) Mov Disord , vol.12 , Issue.2 , pp. 175-182
    • Larsen, J.P.1    Boas, J.2
  • 55
    • 0017729733 scopus 로고
    • Deprenyl in Parkinson's disease
    • Lees AJ, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson's disease. Lancet 1977;2(8042):791-5
    • (1977) Lancet , vol.2 , Issue.8042 , pp. 791-795
    • Lees, A.J.1    Shaw, K.M.2    Kohout, L.J.3
  • 56
    • 0023507276 scopus 로고
    • Deprenyl versus placebo in Parkinson disease: A double-blind study
    • Lieberman AN, Gopinathan G, Neophytides A, Foo SH. Deprenyl versus placebo in Parkinson disease: a double-blind study. NY State J Med 1987;87(12):646-9
    • (1987) NY State J Med , vol.87 , Issue.12 , pp. 646-649
    • Lieberman, A.N.1    Gopinathan, G.2    Neophytides, A.3    Foo, S.H.4
  • 57
    • 3242784708 scopus 로고
    • Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease
    • Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988;11(1):45-55
    • (1988) Clin Neuropharmacol , vol.11 , Issue.1 , pp. 45-55
    • Golbe, L.I.1    Lieberman, A.N.2    Muenter, M.D.3
  • 58
    • 0344758978 scopus 로고    scopus 로고
    • A new low-dose formulation of selegiline: Clinical efficacy, patient preference and selectivity for MAO-B inhibition
    • Clarke A, Johnson ES, Mallard N, et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm 2003;110(11):1257-71
    • (2003) J Neural Transm , vol.110 , Issue.11 , pp. 1257-1271
    • Clarke, A.1    Johnson, E.S.2    Mallard, N.3
  • 59
    • 2342426425 scopus 로고    scopus 로고
    • Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study
    • Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004;19(4):426-32
    • (2004) Mov Disord , vol.19 , Issue.4 , pp. 426-432
    • Waters, C.H.1    Sethi, K.D.2    Hauser, R.A.3
  • 60
    • 34848857679 scopus 로고    scopus 로고
    • Selegiline orally disintegrating tablets in patients with Parkinson disease and 'wearing off' symptoms
    • Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and 'wearing off' symptoms. Clin Neuropharmacol 2007;30(5):295-300
    • (2007) Clin Neuropharmacol , vol.30 , Issue.5 , pp. 295-300
    • Ondo, W.G.1    Sethi, K.D.2    Kricorian, G.3
  • 61
    • 34247324279 scopus 로고    scopus 로고
    • Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease
    • Lew MF, Pahwa R, Leehey M, et al. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. Curr Med Res Opin 2007;23(4):741-50
    • (2007) Curr Med Res Opin , vol.23 , Issue.4 , pp. 741-750
    • Lew, M.F.1    Pahwa, R.2    Leehey, M.3
  • 62
    • 0025892067 scopus 로고
    • Gastrointestinal symptoms in Parkinson's disease
    • Edwards LL, Pfeiffer RF, Quigley EM, et al. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991;6(2):151-6
    • (1991) Mov Disord , vol.6 , Issue.2 , pp. 151-156
    • Edwards, L.L.1    Pfeiffer, R.F.2    Quigley, E.M.3
  • 63
    • 23044514579 scopus 로고    scopus 로고
    • Clinical pharmacology of rasagiline: A novel, second-generation propargylamine for the treatment of Parkinson disease
    • Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 2005;45(8):878-94
    • (2005) J Clin Pharmacol , vol.45 , Issue.8 , pp. 878-894
    • Chen, J.J.1    Swope, D.M.2
  • 64
    • 1542317394 scopus 로고    scopus 로고
    • Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline
    • Bar Am O, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004;355(3):169-72
    • (2004) Neurosci Lett , vol.355 , Issue.3 , pp. 169-172
    • Bar, A.O.1    Amit, T.2    Youdim, M.B.3
  • 65
    • 33744990845 scopus 로고    scopus 로고
    • The need for neuroprotective therapies in Parkinson's disease
    • Poewe W. The need for neuroprotective therapies in Parkinson's disease. Neurology 2006;66(Suppl 4):S2-9
    • (2006) Neurology , vol.66 , Issue.SUPPL. 4
    • Poewe, W.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.